Nanjing, China., June 1, 2019-IASO Biotherapeutics(IASO Bio), a clinical stage biotechnology company advancing the development of innovative therapies for cancer, today announced that IASO Bio will give an oral presentation with title 'Efficacy and Safety of Fully Human BCMA Targeting CAR T Cell Therapy in Relapsed Refractory Multiple Myeloma' (abstract # S827, publication # 929) at 24th Congress of the European Hematological Society in Amsterdam, Netherlands on June 13-16.
For more information, please visit:https://ehaweb.org/congress/reports/eha24-digital-congress-report/
